News | Nuclear Imaging | April 20, 2016

Top U.K. Cancer Center Chooses Mirada Medical Technology

Agreement will bring proton therapy, MR-guided linear accelerators and PET/MR technology to U.K. hospital

Mirada Medical, The Christie Hospital, England, PET-MRI, radiation therapy

April 20, 2016 — Mirada Medical announced a new agreement to work with the clinicians and physicists at The Christie Hospital in Manchester, England, a world-renowned centre for complete cancer care. The Christie is the only U.K. hospital that will be treating cancer patients with proton therapy and magnetic resonance imaging (MRI)-guided linear accelerators (LINAC), whilst benefiting from the latest advancements in diagnostics with positron emission tomography (PET)/MRI.

With Mirada specializing in software to enable collaboration between departments and treatment methods, this is a natural relationship that will support fundamental changes in treatment protocols, reducing time to treatment whilst improving clinical confidence and efficacy.

“We have chosen Mirada as strategic partner to develop multimodality imaging solutions because of the quality of their software, allowing rapid translation of novel techniques into our clinic while also providing the possibility to efficiently integrate workflows for the different treatment techniques that are available at our site,” said Prof. Marcel Van Herk, chair in radiotherapy physics at the University of Manchester and The Christie NHS Foundation Trust.

For more information: www.mirada-medical.com

Related Content

California Protons Cancer Therapy Center Begins Breast Cancer Study Enrollment
News | Proton Therapy | April 25, 2019
California Protons Cancer Therapy Center announced two major efforts representing significant steps forward in breast...
Philips Unveils IntelliSpace Radiation Oncology at ESTRO 2019
News | Oncology Information Management Systems (OIMS) | April 25, 2019
Philips announced IntelliSpace Radiation Oncology, an intelligent patient management solution to manage complexity,...
Accuray Launches Synchrony Motion Tracking and Correction Technology for Radixact System
Technology | Image Guided Radiation Therapy (IGRT) | April 24, 2019
Accuray announced the launch of its Synchrony motion tracking and correction technology to be used with the Radixact...
New Study Redefines Therapeutic Dose Guidelines for Non-Small Cell Lung Cancer
News | Lung Cancer | April 23, 2019
Non-small cell lung cancer is a common cancer for both men and women. Many people who are diagnosed with this type of...
Comparison of state Medicaid fees for radiation oncology services for breast cancer and nonradiation oncology services per the Kaiser Family Foundation Index

Fig. 1: Comparison of state Medicaid fees for radiation oncology services for breast cancer and nonradiation oncology services per the Kaiser Family Foundation Index. (Agarwal et al, Red Journal, 2019) Credit: Elsevier

News | Radiation Therapy | April 22, 2019
April 22, 2019 — A new study finds wide state
Stereotactic Radiosurgery Effective for Pediatric Arteriovenous Malformation Patients
News | Radiation Therapy | April 19, 2019
Ching-Jen Chen, M.D., of the neurosurgery department at the University of Virginia (UVA) Health System, was the winner...
Surgically Guided Brachytherapy Improves Outcomes for Intracranial Neoplasms
News | Brachytherapy Systems | April 18, 2019
Peter Nakaji, M.D., FAANS, general practice neurosurgeon at Barrow Neurological Institute, presented new research on...
ASTRO Applauds Introduction of PIMA Patient Protection Bill
News | Radiology Business | April 15, 2019
The American Society for Radiation Oncology (ASTRO) hailed the introduction of federal legislation that would...
Varian Discloses First Preclinical Results of Flash Therapy in Cancer Treatment
News | Proton Therapy | April 09, 2019
Varian, in partnership with the University of Maryland School of Medicine’s Department of Radiation Oncology and the...
Varian Halcyon Commissioned at MedStar Southern Maryland Hospital Center With IBA's myQA Halo
News | Quality Assurance (QA) | April 04, 2019
IBA (Ion Beam Applications S.A.) announced the successful commissioning of the Varian Halcyon at the Radiation Oncology...